{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:56:51Z","timestamp":1774677411839,"version":"3.50.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/wnf.0000000000000090","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T21:35:00Z","timestamp":1436650500000},"page":"127-131","source":"Crossref","is-referenced-by-count":11,"title":["Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1097","volume":"38","author":[{"given":"Hyman M.","family":"Schipper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Grand'Maison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fraser","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Levental","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Stril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Godin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","article-title":"Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron.","volume":"85","author":"Haider","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1196\/annals.1306.021","article-title":"The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis.","volume":"1012","author":"Levine","year":"2004","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1046\/j.1471-4159.2001.00354.x","article-title":"Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis.","volume":"77","author":"Mehindate","year":"2001","journal-title":"J Neurochem"},{"issue":"1","key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1552-6569.2008.00296.x","article-title":"Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.","volume":"19","author":"Neema","year":"2009","journal-title":"J Neuroimaging"},{"issue":"6","key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0891-5849(89)90066-X","article-title":"The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.","volume":"6","author":"Aruoma","year":"1989","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"R6-2-20210203","first-page":"513","article-title":"Acetylcysteine: a drug that is much more than a mucokinetic.","volume":"42","author":"Ziment","year":"1988","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","article-title":"Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.","volume":"141","author":"Rushworth","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"1","key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1740-2557-2-4","article-title":"N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats.","volume":"2","author":"Stanislaus","year":"2005","journal-title":"J Autoimmune Dis"},{"issue":"4","key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1179\/1351000211Y.0000000007","article-title":"Aminoguanidine and N-acetyl-cysteine supress oxidative and nitrosative stress in EAE rat brains.","volume":"16","author":"Ljubisavljevic","year":"2011","journal-title":"Redox Rep"},{"issue":"1","key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1385\/JMN:27:1:125","article-title":"Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.","volume":"27","author":"Gilgun-Sherki","year":"2005","journal-title":"J Mol Neurosci"},{"issue":"8","key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","article-title":"Controlled trial of N-acetylcysteine for patients with probable Alzheimers disease.","volume":"57","author":"Adair","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1212\/WNL.59.9.1447","article-title":"N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects.","volume":"59","author":"Edwards","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.","volume":"317","author":"Bornstein","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"EuropeanCanadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imagingmeasured disease activity and burden in patients with relapsing multiple sclerosis. EuropeanCanadian Glatiramer Acetate Study Group.","volume":"49","author":"Comi","year":"2001","journal-title":"Ann Neurol"},{"issue":"4","key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.57.4.731","article-title":"Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes.","volume":"57","author":"Filippi","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.","volume":"6","author":"Johnson","year":"2000","journal-title":"Mult Scler"},{"issue":"4","key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1352458506070704","article-title":"Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the EuropeanCanadian double-blind, placebo-controlled, MRI-monitored trial.","volume":"13","author":"Rovaris","year":"2007","journal-title":"Mult Scler"},{"issue":"3","key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols.","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"issue":"5","key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.47.5.1264","article-title":"Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine.","volume":"47","author":"Hurd","year":"1996","journal-title":"Neurology"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0076-6879(99)00118-4","article-title":"Protein carbonyl measurement by enzyme-linked immunosorbent assay.","volume":"300","author":"Winterbourn","year":"1999","journal-title":"Methods Enzymol"},{"issue":"3-4","key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0891-5849(91)90076-F","article-title":"2nd. Quantification of noncyclooxygenase derived prostanoids as a marker of oxidative stress.","volume":"10","author":"Morrow","year":"1991","journal-title":"Free Radic Biol Med"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0076-6879(99)00123-8","article-title":"8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage.","volume":"300","author":"Helbock","year":"1999","journal-title":"Methods Enzymol"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jchromb.2009.02.051","article-title":"Isocratic rapid liquid chromatographic method for simultaneous determination of carotenoids, retinol, and tocopherols in human serum.","volume":"877","author":"Thibeault","year":"2009","journal-title":"J Chromatog B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/WCO.0b013e328122de1b","article-title":"Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.","volume":"20","author":"Costello","year":"2007","journal-title":"Curr Opin Neurol"},{"issue":"1-2","key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2006.08.019","article-title":"Combination therapy in multiple sclerosis.","volume":"259","author":"Fernandez","year":"2007","journal-title":"J Neurol Sci"},{"issue":"6","key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1185\/030079907X187838","article-title":"Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.","volume":"23","author":"Stuart","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1352458507085759","article-title":"Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.","volume":"14","author":"Vollmer","year":"2008","journal-title":"Mult Scler"},{"issue":"2","key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.52.2.426","article-title":"N-acetylcysteine therapy for Unverricht-Lundborg disease.","volume":"52","author":"Selwa","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0920-1211(00)00096-6","article-title":"Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies.","volume":"40","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsy Res"},{"issue":"1-2","key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0378-5955(00)00036-8","article-title":"In vitro effects of hydrogen peroxide on the cochlear neurosensory epithelium of the guinea pig.","volume":"143","author":"Dehne","year":"2000","journal-title":"Hear Res"},{"issue":"7","key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00005537-200107000-00005","article-title":"L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity.","volume":"111","author":"Feghali","year":"2001","journal-title":"Laryngoscope"},{"issue":"4","key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ana.10684","article-title":"Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy.","volume":"54","author":"Klein","year":"2003","journal-title":"Ann Neurol"},{"issue":"1-2","key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0378-5955(00)00176-3","article-title":"Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla.","volume":"149","author":"Kopke","year":"2000","journal-title":"Hear Res"},{"issue":"2","key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0006-8993(02)04205-1","article-title":"Protection from noise-induced lipid peroxidation and hair cell loss in the cochlea.","volume":"966","author":"Ohinata","year":"2003","journal-title":"Brain Res"},{"issue":"8","key":"R39-2-20210203","first-page":"397","article-title":"Iron deposits surrounding multiple sclerosis plaques.","volume":"106","author":"Craelius","year":"1982","journal-title":"Arch Pathol Lab Med"},{"issue":"1-2","key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0006-8993(97)00470-8","article-title":"Iron deposits in multiple sclerosis and Alzheimers disease brains.","volume":"760","author":"LeVine","year":"1997","journal-title":"Brain Res"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:10:14Z","timestamp":1620976214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201507000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000090","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}